Guideline Summary for Tirzepatide (Mounjaro) Use in Type 2 Diabetes

Pre‑Treatment Screening & Contraindications

Assess adult patients with type 2 diabetes for a history of acute or chronic pancreatitis before initiating tirzepatide. 1
Evaluate for current gallstones or biliary disease; consider a baseline abdominal ultrasound in patients who are female, middle‑aged, have obesity, or hypertriglyceridemia. 1
Measure fasting triglycerides; if ≥ 500 mg/dL, counsel strict alcohol avoidance to reduce pancreatitis risk. 1
Document alcohol consumption patterns and advise moderation or abstinence during tirzepatide therapy. 1

Nausea (12–25 %), diarrhea (12–17 %), vomiting (5–9 %), constipation (6–7 %), and decreased appetite (5–11 %) are the most common adverse events; they peak during dose escalation and usually improve with continued treatment. 3
Evaluate gastrointestinal symptoms at each dose‑escalation visit and then monthly for the first three months of therapy. 3
Provide dietary counseling: recommend smaller meals, stop eating when full, avoid high‑fat or spicy foods, and limit alcohol and carbonated beverages. 3
Manage constipation by encouraging adequate hydration and increased dietary fiber intake. 3

Discontinue tirzepatide immediately if the patient develops severe or persistent abdominal pain and assess for acute pancreatitis. 1
Isolated elevations of lipase or amylase without clinical signs of pancreatitis should not alone trigger a diagnosis. 1

The highest incidence of cholelithiasis and biliary complications occurs within the first 1–6 months of therapy, especially during rapid weight loss. 1
In patients reporting right‑upper‑quadrant pain, nausea, or vomiting, obtain gallbladder imaging and arrange clinical follow‑up. 1

Monitor renal function in patients experiencing severe nausea, vomiting, or diarrhea that could lead to volume depletion and acute kidney injury. 1
Observe for hypoglycemia, particularly in patients receiving concomitant insulin or sulfonylureas. 1

Approximately 25 % of tirzepatide‑induced weight loss is attributable to lean‑mass loss; therefore, implement strategies to protect muscle. 4
Prescribe protein intake of 1.2–1.6 g per kilogram of ideal body weight per day, distributed as 25–30 g of high‑quality protein per meal (e.g., lean meats, fish, eggs, dairy, legumes). 4
Initiate resistance training 2–3 times per week at the start of tirzepatide therapy (rather than after weight‑loss plateau) to stimulate muscle protein synthesis. 4
Provide a daily multivitamin‑mineral supplement to offset reduced food intake. 4
Supplement vitamin D (600–800 IU daily) and calcium (1,000–1,200 mg daily, divided doses) for bone health. 4
Consider vitamin E (15 mg α‑tocopherol daily) for neuropathy prevention if fat‑soluble vitamin deficiency is suspected. 4

Skipping the 2.5 mg starter dose or accelerating titration – always begin with 2.5 mg weekly and wait a full 4 weeks before each escalation to reduce gastrointestinal adverse events. 3
Failing to adjust insulin or sulfonylurea doses – proactively reduce these agents at tirzepatide initiation to prevent severe hypoglycemia. 3
Overlooking gallbladder disease in high‑risk patients – maintain heightened vigilance and consider baseline ultrasound in female, middle‑aged, obese, or hypertriglyceridemic individuals. 1
Ignoring oral‑contraceptive interactions – advise females to switch to non‑oral contraception or add a barrier method during initiation and each dose escalation, as tirzepatide may reduce oral contraceptive absorption. 2
Delaying resistance training – start resistance exercise at treatment onset to preserve lean mass during early weight‑loss phase. 4

Tirzepatide reduces HbA1c by 1.0–2.4 % in a dose‑dependent manner and demonstrates superior glycemic efficacy compared with semaglutide 1 mg, basal insulin, and prandial insulin. 5
Mean weight loss ranges from 12.8 % (10 mg weekly) to 14.7 % (15 mg weekly), markedly greater than the 3.2–3.4 % observed with placebo. 2
When used without insulin or sulfonylureas, tirzepatide carries a low risk of hypoglycemia and does not increase major adverse cardiovascular events. 5